MFSD13A

Across TCGA pan-cancer cohorts, MFSD13A RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated MFSD13A data layer compared with 3 for mutation status and 2 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher MFSD13A RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MFSD13A expression acts as an unfavorable survival marker, although some lineages such as SCLC and LGG show a favorable association.

ACC, SCLC, and THCA are the cancer types where MFSD13A RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.765	0.975	<.001	125	view →
SCLC	OS	Median	All	0.507	0.209	<.001	80	view →
THCA	DFS	Tertile	All	0.731	0.931	<.001	53	view →
LGG	OS	Median	All	0.947	0.839	<.001	47	view →
LIHC	DFS	Tertile	All	0.461	0.598	.005	45	view →
STAD	DFS	Median	III,IV	0.665	0.509	.006	32	view →
KIRC	DFS	Tertile	IV	0.329	0.553	.021	21	view →
LAML	DFS	Median	All	0.474	0.651	.010	14	view →
SARC	OS	Tertile	All	0.667	0.398	.008	13	view →
BRCA	OS	Tertile	III,IV	0.939	0.868	.027	13	view →
ESCA	OS	Tertile	II,III,IV	0.376	1.000	.034	9	view →
HNSC	OS	Median	IV	0.417	0.264	.010	7	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

MFSD13A–ACC (OS)

Open the ACC breakdown →